Danny Sullivan

About

Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
97 POSTS

/

0 COMMENTS

Articles

Building an artificial immune system

DoD-funded ThirdLaw Technologies to harness the power of ‘spiroligomers’ to rapidly build new small molecules for Longevity therapies. Far from the world of stock market...

“Avoid the use of DQ as a senolytic therapy”

Forever Healthy Foundation issues risk-benefit analysis on dasatinib + quercetin as a senolytic. The Forever Healthy Foundation today published its latest risk-benefit analysis, which explores...

Real-time tracking of 400+ Longevity biomarkers

Longevity InTime aims to track 400+ biomarkers of health in ‘real time’ ... starting with millionaires (as both users and investors). From wearable devices and...

Hereafter: conversations in the afterlife

We speak to Dadbot creator James Vlahos about using conversational AI to better remember loved ones who have passed away; a very interesting step...

Longevity and the Singularity

Consciousness in the cloud? Where science fact and fiction collide. While the principle focus of Longevity is undoubtedly the extension of healthy human lifespan, there...

Longevity Leaders World Congress goes virtual

Annual Longevity conference gets a digital makeover as the community adapts to COVID-19. With much of the world still in some form of lockdown, the...

New young blood plasma research creates a stir

Indian start-up Nugenics Research to commercialise “Elixir” after showing 54% age reversal in animal study. The topic of using blood plasma to address human Longevity...

Let’s get the CAR-T started

EXUMA readies solid tumour cell therapy treatment for the clinic. With the cell therapy market predicted to triple in size over the next five years,...

The next generation of Longevity investment

What’s driving Kingsley Advani to get involved in the fight against aging? What do Juvenescence, Oisín Biotechnologies, Volumetric and GEn1E Lifesciences have in common? Yes,...